" class="no-js "lang="en-US"> Maven Clinic Announces Research & Investments in Innovation
Monday, February 26, 2024

Maven Clinic Announces New Clinical Research and Investments in Innovation to Advance Care Model for Women’s and Family Health

Maven Clinic, the world’s largest virtual clinic for women’s and family health, has announced several clinical innovation milestones, including publishing results from two new peer-reviewed studies and appointing its next Visiting Scientist to deepen insights into perinatal mental health. These advancements demonstrate how Maven is redesigning the care model for women’s and family health, centering the needs of members while driving down healthcare spend for its partners.

“To deliver on its promise, digital health must provide more than an improved user experience — it has to impact the generational problems of healthcare, including inequity and high costs,” said Kate Ryder, founder and CEO of Maven Clinic. “Maven’s platform has a strong clinical foundation that is delivering industry-leading results for our partners on the issues that matter most.”

Maven’s family-building programs reduce costs for employers and health plans, while bringing together clinical, emotional and financial support to improve health and business outcomes for its members. The company’s care model has demonstrated that it has lowered C-section rates by up to 20%, reduced NICU (neonatal intensive care unit) admissions by up to 28%, and helped as many as 25% of its fertility members to achieve pregnancy without assisted reproductive technology. Maven’s ROI calculation methodology for its maternity and fertility programs was independently reviewed and validated by Milliman, Inc., as described in the associated reports (maternity, fertility).

“Digital care models have as much potential to impact people’s health as drugs or devices, and should be developed with a high standard of scientific rigor,” said Dr. Neel Shah, Chief Medical Officer of Maven Clinic. “Maven has built evidence-based programs that close critical gaps in access to services while measuring and publicly reporting our work.”

In addition to announcing new research, Maven has welcomed a new clinician innovator, Dr. Constance Guille, Professor in the Department of Psychiatry and Behavioral Sciences and Obstetrics and Gynecology at Medical University of South Carolina, as its second Visiting Scientist. In this role, Dr. Guille will bring her expertise as a reproductive psychiatrist to help advance Maven’s clinical research roadmap and provide strategic input on care model design, with a focus on mental health.

“Having seen the devastating effects of unrecognized and untreated maternal mental health disorders, I believe there is a tremendous need and promise for using digital health to integrate patient-centered maternal behavioral health treatment into routine prenatal care,” said Dr. Guille. “I am excited to share my insights with Maven to further advance the company’s maternal mental health care model.”

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more